FDA
-
-
-
-
-
-
-
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Lantern Pharma announces roadmap for withZeta.ai AI platform expansion
-
-
-
-
-
-
-
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSi
-
-
-
-
-
-
-
Lantern Pharma's LP-284 gets FDA orphan drug status for soft tissue sarcoma
-
-
-
-
-
-
-
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
-
-
-
-
-
-
-
Lantern Pharma completes FDA meeting for pediatric brain cancer trial
-
-
-
-
-
-
-
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

